Novel glutamine antagonists and uses thereof

0580592 - ÚOCHB 2024 RIV eng P - Patent Document
Slusher, B. - Rais, R. - Majer, Pavel - Tenora, Lukáš - Novotná, Kateřina - Alt, J.
Novel glutamine antagonists and uses thereof.
2022. Owner: The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i. Date of the patent acceptance: 24.08.2022. Patent Number: EP3692015. Territorial Protection: evropský patent podle Evropské patentové úmluvy ,mezinárodní patentová ochrana dle Smlouvy o patentové spolupráci.
R&D Projects: GA MŠMT LTAUSA18166
Institutional support: RVO:61388963
Keywords : glutamine antagonists * 6-diazo-5-oxo-L-norleucine * prodrug strategies
OECD category: Organic chemistry
https://worldwide.espacenet.com/patent/search/family/065994832/publication/EP3692015B1?q=EP3692015B1

Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.
Permanent Link: https://hdl.handle.net/11104/0349359